Item 2.02. Results of Operations and Financial Conditions

On January 20, 2021, Inovio Pharmaceuticals, Inc. (the "Company") filed with the Securities and Exchange Commission ("SEC") a preliminary prospectus supplement (the "Preliminary Prospectus Supplement") in connection with a proposed public offering of shares of its common stock, which contained information regarding the Company's preliminary estimates of its cash, cash equivalents and short-term investments and shares of common stock outstanding as of December 31, 2020. The Company preliminarily estimates that its cash, cash equivalents and short-term investments as of December 31, 2020 was approximately $412 million and that it had 186,851,493 shares of common stock outstanding as of December 31, 2020. These preliminary estimates are not a comprehensive statement of the Company's financial results for the fiscal year ended December 31, 2020 and have not been audited, reviewed or compiled by the Company's independent registered public accounting firm. The Company's actual cash, cash equivalents and short-term investments and shares of common stock outstanding as of December 31, 2020 may differ from these estimates due to the completion of the Company's year-end closing and auditing procedures.

The information provided in this Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

The Preliminary Prospectus Supplement contained an updated description of certain aspects of the Company's business, certain legal proceedings and certain risk factors. Accordingly, the Company is filing this information with this Current Report on Form 8-K for the purpose of supplementing and updating disclosures contained in the Company's prior filings with the SEC, including those discussed in the Company's most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 12, 2020, as supplemented by the Company's subsequent filings with the SEC. The updated disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.






Exhibit
  No.       Exhibit Description

99.1          Updated Corporate Disclosure.

104         Cover page interactive data file (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses